Home Study Details

    Program Type

    Home Study


    1.5 Contact Hour(s)

    Release Date

    Friday, November 16, 2018

    Offline Date

    Sunday, May 16, 2021

    ACPE Expiration Date

    Tuesday, November 16, 2021

    Target Audience




    • Overview

      Psoriasis is the most common autoimmune condition in the US, affecting 7.5 million people. It is a complex, genetically linked disease; 1 in every 3 patients with psoriasis has a relative with the condition. The human and economic tolls are signifi­cant. Patients with psoriasis have lower quality of life scores, along with increased occurrences of depression, anxiety and suicidal ideation. In the US, more than $63 million is spent an­nually in direct healthcare costs for psoriasis.

      Currently, there is no cure; however, a variety of treat­ments (topical, systemic, phototherapy) are available to manage symptoms, minimize disease progression, and improve quality of life. Since the early 2000s, research into the immunopatho­genesis of psoriasis has led to the development of biologic agents that target specific components of the immune system. Despite the availability of multiple treatments, patients with psoriasis in the US are often under treated, or untreated. Untreated or under treated psoriasis leads to disseminated disease and poten­tially, to joint impairment in the form of psoriatic arthritis (PsA), which causes pain and stiffness of affected joints.

      While psoriasis treatment guidelines recommend that trained specialty providers prescribe systemic therapies for patients with this disease, community practitioners should have a sufficient knowledge base to monitor treatment. Frequent patient interactions allow community practitioners, including pharmacists and nurse practitioners, to play an important role in psoriasis management. This issue will review basic information about cutaneous psoriasis and summarize various treatments, so practitioners can better manage and educate patients.


      • Homestudy PDF :   18248H01.pdf

      Financial Support By

    • Pharmacist

      Describe psoriasis symptoms and how body surface area and the Psoriasis Area Severity Index (PASI) are used in assessing psoriasis severity.
      List commonly used topical treatments. Counsel patients regarding administration, side effects, and precautions.
      Discuss the epidemiology and contributing factors for the development of psoriasis.
      Compare and contrast systemic treatments used for psoriasis, including effectiveness, side effects, and precautions.
    • Activity Type


      CE Broker


      Universal Activity Number

      Pharmacist 0798-9999-18-248-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Celia  MacDonnell, BS Pharmacy, PharmD
      Clinical Professor at the College of Pharmacy, University of Rhode Island; Adjunct Associate Professor of Family Medicine at the Alpert Medical School at Brown University.

    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones

    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Firefox 3.0.3 or higher
    Adobe Acrobat Reader

    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).